The mechanism of inhibition of human RNA polymerase by four rifamycin derivatives was investigated. Derivative AF/013 (3-formyl rifamycin SV: 0-noctyloxime) with strong hydrophobic side chains prevents the polymerase from binding to DNA and also affects the size of RNA synthesized. Derivative benzyl-2'-methylpyrrolo[3,2-cJ-4-desoxy-rifamycin SV) only affects RNA synthesis when RNA polymerase has been previously incubated with the drug or when the reaction was performed at high salt concentration [0.14 M (NH4)2-S041-Our results suggest that these drugs exert their inhibitory actions by binding to the enzyme instead of DNA.
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The antibiotic rifampicin inhibits DNA-dependent RNA polymerase obtained from prokaryotic cells, but it has no effect on RNA polymerase isolated from higher organisms (1) . One rifamycin derivative, AF/013 (3-formyl rifamycin SV:O-n-octyloxime) synthesized by Lepetit S.p.A., Milan, Italy, can inhibit DNA-dependent RNA polymerases isolated from rat liver (2) and calf thymus (3) . This drug inhibits initiation of RNA chains (2, 3) . We report studies of the action of rifampicin and four rifamycin derivatives: AF/05 (3-formyl rifamycin SV :O-[diphenylmethyl] oxime), AF/013, PR/19 (3'-acetyl-1'-benzyl-2'-methylpyrrolo [2,3-c] 4 -desoxyrifamycin SV), and PR/14 (3'-acetyl-1', 2'-dimethylpyrrolo [3,2-c ]-4-desoxy-rifamycin SV) on DNA-dependent RNA polymerase II (or B) isolated from lymphocytes of patients with chronic lymphocytic leukemia.
In vitro RNA synthesis by DNA-dependent RNA polymerase proceeds in a stepwise manner (3, 4) . The first step involves binding of the enzyme to the DNA template; the subsequent steps are chain initiation, chain elongation, and chain termination. Rifampicin inhibits Escherichia coli RNA polymerase after binding of polymerase to the DNA and before formation of the first internucleotide bonds (1, 5, 6 into C13CCOOH-insoluble material in 10 min. Antibiotics were dissolved in dimethyl formamide to a concentration of 10 mg/ml as stock solution, and were added to the assay mixture at the desired concentration. Equivalent amounts of dimethyl formamide were also added to the control samples. Drug concentration of 200 ,ug/ml corresponds to about 0.23 mM. The reactions were incubated at 370 for 10 min, and 5 ml of cold 5% C13CCOOH containing 0.01 M sodium pyrophosphate were added to stop the reaction. An equal amount of the appropriate drug was added to the control sample at this time in order to compensate for the quenching caused by the color of the drug. After standing at 00 for at least 15 min, C13CCOOH-precipitable material were collected on glass membrane filters, washed with 5% C13CCOOH-0.01 M sodium pyrophosphate, and counted in a liquid scintilla- RNA polymerase II from chronic lymphocytic leukemics was preincubated with the desired amount of antibiotics at 370 for 2 min before the assay mixture was added to start the reaction. The reaction mixture and assay conditions were the same as described in the legend of 200 ,ug/ml, exerted no effects on polymerase from chronic lymphocytic leukemics regardless of whether they were added before or after initiation of RNA synthesis. This agrees with results of other laboratories that rifampicin has no effect on the RNA polymerase isolated from higher organisms (1) .
Studies of RNA synthesis as a function of drug concentration are shown in Table 2 at a concentration of 0.1 M (NH4)2SO4. These results are summarized in Table 3 , where the conditions of RNA synthesis are shown in the first column. In experiment A of Table 3 , RNA polymerase II of chronic lymphocytic leukemics was added to the reaction mixture and incubated at 370 for 2 min before addition of drugs or drug solvent, dimethyl formamide. Reaction mixtures were then incubated an additional 13 min at 37°. In experiment B, a 100-fold excess of nonradioactive UTP was added at the time of the drug or solvent addition and subsequent incubation was as above, 13 min at 37°. The data in Table 3 show the average molecular weight as compared to the 2-min control, and the percentage increase (16) . Therefore, the size of RNA synthesized in the presence of various drugs should follow the following trends:
Reinitiation inhibited > Solvent control > Elongation inhibited > 2-min control.
If initiation and elongation were both affected during RNA synthesis, we would expect the size of the RNA to be somewhere between the initiation-inhibited and elongationinhibited size distributions. In experiment B, where unlabeled UTP is used in chase experiments, the size of RNA product should not be affected by reinitiation. Therefore, the order of size in this experiment can be arranged as follows:
Reinitiation inhibited = Solvent control > Elongation inhibited > 2-min control.
In Table 3 2 min before addition of (200 ,ug/ml) 14 reaction mixture Assay mixtures are as described in Table 1 with the exception that 6 ug of lymphocyte ['H]DNA (1000 cpm/iug) was substituted for calf-thymus DNA and unlabeled UTP was substituted for tritium-labeled UTP. Final (NH4)2SO4 concentration was 0.09 M. Enzyme was preincubated with the reaction mixture or drug at 370 for 2 min, then the drug or reaction mixture was added and incubated at 37°for 2 additional min. The amount of DNA-enzyme complex was determined by filtration through Millipore filters as described by Jones and Berg (9) . The blank containing the reaction mixture without enzyme showed 40 cpm retained on filters. Table 3 , and (NH4)2SO4 concentrations used are indicated in the figure. 50 Units of enzyme were incubated with 1.6-ml reaction mixture at 370 for 5 min. Drugs were then added and reaction was carried out for additicinal time period as indicated in the figure. DNAenzyme complex was measured by the binding method of Jones and Berg (9) . The amount of DNA retained on the Millipore filter at the time of addition of drug was set to be 100%. Meilhac et al. (3) reported the effect of rifamycin derivatives on calf-thymus RNA polymerase. They concluded that initiation, but not elongation, was inhibited by AF/05, and that both the primary binding of the enzymes to DNA and a temperature-dependent step were inhibited. If AF/05 and AF/013 act in the same way, then our results are at variance with the report of Meilhac et al., whose conclusion that AF/05 does not effect elongation was based on the finding that AF/05 inhibits RNA synthesis in the same manner as polyethylene sulfate. Since the effect of polyethylene sulfate on chain elongation has not been clearly established (14) , the interpretation that it effects chain elongation is questionable. The data presented in Table 3 clearly showed that AF/013 inhibits binding and elongation (size increased 65% as much as the dimethylformamide control). The strongly hydrophobic side chain of AF/05 (3) might suggest why it does not prevent the release of enzyme from DNA. However, PR/19 affects RNA synthesis by preventing binding of enzyme to DNA. This occurs either after prior incubation at low-salt concentration with enzyme or at high-salt [0.14 M (NH4)SO4] concentration, suggesting that the interaction between PR/19 and the enzyme is very weak, or it is a very slow process compared to the interaction between enzyme and DNA. Therefore, when the enzyme is released during transcription in low-salt medium it can then bind again to DNA before PR/19 has formed a stable complex with the enzyme. The higher the salt concentration, the faster is the dissociation rate of the enzyme-DNA complex (15) , which makes RNA polymerase more sensitive to PR/19 in high-salt solution.
